The Phase 3 trial results are out, and Retatrutide is seriously a miracle drug.

Significant Weight Loss with 12mg Dosage
• A 28.3% reduction in body weight was observed over 80 weeks with a 12mg dosage.
• This equates to an average weight loss of 70.3 pounds (31.9 kg).
• Notably, 45.3% of patients achieved a weight loss exceeding 30%, a level comparable to outcomes typically seen with bariatric surgery.
• For patients with higher baseline BMIs, a 30.3% weight loss (85 lbs) was recorded at 104 weeks.
• Furthermore, 65.3% of patients receiving the 12mg dosage transitioned below the obesity BMI threshold.

Efficacy and Tolerability of 4mg Dosage
• With a 4mg dosage over 80 weeks, a 19% weight loss (47.2 lbs) was achieved, accompanied by a lower dropout rate compared to the placebo group (4.1% vs 4.9%).

Metabolic Health and Safety Profile
• Significant improvements were also noted in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP levels.
• No adverse cardiac or hepatic signals were detected.

Retatrutide’s going to be the next Ozempic when it’s prescribed to the public.

Research Purposes Only Disclaimer

This website (valtakpeptides.com) is provided strictly for research and informational purposes only. No products are sold on this site, and no purchases can be made here.

All information provided on this site is intended exclusively for research and development purposes. Any referenced products are strictly not for human consumption or therapeutic use. These products are not approved by the U.S. Food and Drug Administration (FDA), and no statements on this website have been evaluated by the FDA. The information and any referenced products are not intended to diagnose, treat, cure, or prevent any disease or medical condition.